TY - JOUR
T1 - Factors associated with variance in compliance with a sentinel lymph node dissection quality measure in early-stage breast cancer
AU - Olaya, Windy
AU - Wong, Jan
AU - Morgan, John W.
AU - Truong, Caitlyn
AU - Roy-Chowdhury, Sharmila
AU - Kazanjian, Kevork
AU - Lum, Sharon
N1 - Funding Information:
ACKNOWLEDGMENT This study was supported in part by NCI/ SEER contracts No. N01-PC-35136, N01-PC-35139, and N02-PC-15105, CDC/National Program for Cancer Registries contract No. U58DP000807-01, and the California Department of Public Health, Cancer Surveillance Branch.
PY - 2010/10
Y1 - 2010/10
N2 - Background: Guidelines recommend sentinel lymph node dissection (SLND) for patients with clinical stage I/IIA/IIB breast cancer; however, a significant fraction of patients do not undergo this procedure. We sought to identify factors associated with noncompliance with the SLND benchmark in early-stage breast cancer. Materials and Methods: All patients with an initial diagnosis of Stage I/IIA/IIB invasive breast carcinoma who were treated between 2004 and 2007 with records in the California Cancer Registry were evaluated. Odds ratios evaluating receipt of SLND were compared for sex, age, stage, socioeconomic status (SES), race/ethnicity, surgery type, year of diagnosis, and hospital cancer program approval from the American College of Surgery (ACOS). Results: Of 55,207 patients identified, 66% underwent SLND. On multivariable analyses, patients were significantly less likely to undergo SLND if they were >65 years of age, stage IIA or IIB, of lower socioeconomic status, of nonwhite race/ethnicity, treated with total mastectomy, treated during 2004-2005, or at a non-ACOS approved institution. Conclusions: SLND use in California has increased over time; however, only two-thirds of eligible patients undergo this recommended procedure. Using SLND as a quality measure demonstrates significant disparities that have implications not only for patient and provider education, but also for health care policy and reform. © 2010 Society of Surgical Oncology.
AB - Background: Guidelines recommend sentinel lymph node dissection (SLND) for patients with clinical stage I/IIA/IIB breast cancer; however, a significant fraction of patients do not undergo this procedure. We sought to identify factors associated with noncompliance with the SLND benchmark in early-stage breast cancer. Materials and Methods: All patients with an initial diagnosis of Stage I/IIA/IIB invasive breast carcinoma who were treated between 2004 and 2007 with records in the California Cancer Registry were evaluated. Odds ratios evaluating receipt of SLND were compared for sex, age, stage, socioeconomic status (SES), race/ethnicity, surgery type, year of diagnosis, and hospital cancer program approval from the American College of Surgery (ACOS). Results: Of 55,207 patients identified, 66% underwent SLND. On multivariable analyses, patients were significantly less likely to undergo SLND if they were >65 years of age, stage IIA or IIB, of lower socioeconomic status, of nonwhite race/ethnicity, treated with total mastectomy, treated during 2004-2005, or at a non-ACOS approved institution. Conclusions: SLND use in California has increased over time; however, only two-thirds of eligible patients undergo this recommended procedure. Using SLND as a quality measure demonstrates significant disparities that have implications not only for patient and provider education, but also for health care policy and reform. © 2010 Society of Surgical Oncology.
KW - Lymph Node Excision
KW - Prognosis
KW - Neoplasm Invasiveness
KW - Humans
KW - Middle Aged
KW - Quality Indicators, Health Care
KW - California
KW - Young Adult
KW - Sentinel Lymph Node Biopsy/statistics & numerical data
KW - Guideline Adherence
KW - Aged, 80 and over
KW - Adult
KW - Female
KW - Aged
KW - Patient Compliance
KW - Breast Neoplasms/ethnology
KW - Neoplasm Staging
KW - Practice Guidelines as Topic
UR - https://www.scopus.com/pages/publications/78149275555
UR - https://www.scopus.com/pages/publications/78149275555#tab=citedBy
UR - https://www.mendeley.com/catalogue/fe672b7b-ddec-3782-bb44-d2029a241475/
U2 - 10.1245/s10434-010-1248-0
DO - 10.1245/s10434-010-1248-0
M3 - Article
C2 - 20853050
SN - 1068-9265
VL - 17
SP - 297
EP - 302
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - SUPPL. 3
ER -